Junqiang Lv
Impact in
- Rehabilitation top 10%
- Exercise and Physiological Responses
- Endocrinology top 10%
- Escherichia coli research studies
Papers in
- Oncology 8
- Peptidase Inhibition and Analysis 5
-
- Histone Deacetylase Inhibitors Research 3
- Signaling Pathways in Disease 2
- Epigenetics and DNA Methylation 2
- Co-authors
- Zhi Yao (14 shared papers)Quan Wang (10 shared papers)Rong Lu (8 shared papers)Zhi‐Song Zhang (6 shared papers)Yanjiao Zhou (1 shared paper)Lı Wang (1 shared paper)Xiaolei Li (2 shared papers)Rui Ma (2 shared papers)
- Journals
- Anti-Cancer Drugs (3 papers)Peptides (2 papers)Cell Reports (2 papers)Frontiers in Immunology (2 papers)mBio (1 paper)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Junqiang Lv
27 papers receiving 549 citations
Peers
Comparison fields: 5 of 86
- Rehabilitation 49
- Endocrinology 36
- Biological Psychiatry 12
- Molecular Biology 252
- Complementary and alternative medicine 26
Countries citing papers authored by Junqiang Lv
This map shows the geographic impact of Junqiang Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junqiang Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junqiang Lv more than expected).
Fields of papers citing papers by Junqiang Lv
This network shows the impact of papers produced by Junqiang Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junqiang Lv. The network helps show where Junqiang Lv may publish in the future.
Co-authors
The 25 scholars most cited alongside Junqiang Lv, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 123 | |
| 2 | 2023 | 80 | |
| 3 | 2017 | 42 | |
| 4 | 2019 | 42 | |
| 5 | 2020 | 40 | |
| 6 | 2022 | 39 | |
| 7 | 2020 | 27 | |
| 8 | 2018 | 21 | |
| 9 | 2022 | 21 | |
| 10 | 2021 | 16 | |
| 11 | 2018 | 16 | |
| 12 | 2010 | 16 | |
| 13 | 2024 | 15 | |
| 14 | 2013 | 13 | |
| 15 | 2022 | 10 | |
| 16 | Herbal formula of Bushen Jianpi combined with sorafenib inhibits hepatocellular carcinoma growth by promoting cell apoptosis and blocking the cell cycle. | 2021 | 7 |
| 17 | 2024 | 7 | |
| 18 | 2011 | 4 | |
| 19 | 2025 | 4 | |
| 20 | 2008 | 3 |
About Junqiang Lv
Junqiang Lv is a scholar working on Oncology, Molecular Biology, Endocrinology, Cancer Research and Immunology, having authored 29 papers that have together received 561 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (5 papers), Escherichia coli research studies (3 papers), Urinary Tract Infections Management (3 papers), Histone Deacetylase Inhibitors Research (3 papers), Cancer, Hypoxia, and Metabolism (3 papers), Signaling Pathways in Disease (2 papers), Epigenetics and DNA Methylation (2 papers) and Immune cells in cancer (2 papers). The work is most often cited by research in Rehabilitation (49 citations), Endocrinology (36 citations), Biological Psychiatry (12 citations), Molecular Biology (252 citations) and Complementary and alternative medicine (26 citations). Junqiang Lv has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Zhi Yao, Quan Wang, Rong Lu, Zhi‐Song Zhang, Yanjiao Zhou, Lı Wang, Xiaolei Li, Rui Ma, Huali Zhang and Lijuan Chen. Their work appears in journals such as Anti-Cancer Drugs, Peptides, Cell Reports, Frontiers in Immunology and mBio.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.